Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
J Surg Case Rep ; 2018(10): rjy261, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30310647

RESUMO

Metastases from renal clear cell carcinoma (RCCC) to the head and neck (HN) region are rare, representing 8-14% of all RCCC metastases, with the thyroid gland being the most common site of RCCC metastasis in the HN. Metastatic tumors that are located in the salivary glands have a prevalence of 5%, while the submandibular gland is only involved in 1% of the cases. We present the case of a 74-year-old female patient with metastasis to the submandibular gland, 11 years after radical nephrectomy for a RCCC.

2.
Epidemiol Infect ; 139(11): 1757-63, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21320374

RESUMO

Ventilator-associated pneumonias (VAPs) are a worldwide problem that significantly increases patient morbidity, mortality, and length of stay (LoS), and their effects should be estimated to account for the timing of infection. The purpose of the study was to estimate extra LoS and mortality in an intensive-care unit (ICU) due to a VAP in a cohort of 69,248 admissions followed for 283,069 days in ICUs from 10 countries. Data were arranged according to the multi-state format. Extra LoS and increased risk of death were estimated independently in each country, and their results were combined using a random-effects meta-analysis. VAP prolonged LoS by an average of 2·03 days (95% CI 1·52-2·54 days), and increased the risk of death by 14% (95% CI 2-27). The increased risk of death due to VAP was explained by confounding with patient morbidity.


Assuntos
Unidades de Terapia Intensiva/estatística & dados numéricos , Tempo de Internação/estatística & dados numéricos , Pneumonia Associada à Ventilação Mecânica/mortalidade , Estudos de Coortes , Países em Desenvolvimento/estatística & dados numéricos , Humanos , Índice de Gravidade de Doença
3.
J Colloid Interface Sci ; 338(2): 519-22, 2009 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-19619882

RESUMO

A simple and general method is presented to calculate the equilibrium surface of a liquid that penetrates spontaneously, due to capillarity, in the gap between two vertical corrugated plates. Several properties of the equilibrium solution are discussed and the results are backed by a qualitative experiment.

4.
Phys Rev E Stat Nonlin Soft Matter Phys ; 71(6 Pt 2): 066308, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16089868

RESUMO

This paper presents a theoretical investigation of the low Rayleigh number conjugate natural convection in a slender tilted cylindrical cavity which is embedded in a solid that is subject to a uniform vertical temperature gradient. Two cases have been analyzed; a fluid-filled cavity and a cavity filled with a fluid-saturated porous medium. The temperature of the solid and the velocity, temperature, and pressure in the cavity have been determined by analytically solving the coupled problems within and around the cavity. The effect of the ratio of the thermal conductivity of the material in the cavity to the thermal conductivity of the solid on the structure of the convection flow is discussed. The theoretical results for convection in the fluid-filled cavity are shown to be in good agreement with experimental PIV measurements.

5.
Actas Esp Psiquiatr ; 32(4): 216-21, 2004.
Artigo em Espanhol | MEDLINE | ID: mdl-15232750

RESUMO

INTRODUCTION: The Children Yale-Brown Obsessive- Compulsive Scale (CY-BOCS) constitutes a very good instrument for the evaluation of obsessive-compulsive disorder (OCD) symptoms, by a clinical interview administered to the patient and parent, that includes summary score of the clinician. OBJECTIVE: We are proposing a Spanish version of instrument, which is rated during a brief clinical interview to the parents and the patients. We are presenting data reliability and validity using two out-patient samples. METHODS: After the translation to Spanish, a back translation and adaptation to Spanish of the CY-BOCS, twenty eight out-patients (75 % male) with a mean age 12.1 (+/- 2.7) from two clinical settings on Mexico City evaluated. Reliability was evaluated by computing the internal consistency (Cronbach's alpha) on all interviews. assess interrater agreement, the interviews were videotaped and scored by three independent raters and all of them included both the child and the parent interview. The CY-BOCS total scored was correlated with the K-SADS-PL diagnosis. RESULTS: The CY-BOCS total score for all subjects was 16.5 +/- 9.8. Cronbach's alpha coefficient was 0.87; Pearson correlation of total CY-BOCS score with the K-SADS-PL diagnosis was 0.60 (p < or = 0.05). The intraclass correlations coefficients for the parents, youngsters and clinician 0.96, 0.94 and 0.92, respectively. CONCLUSIONS: The Spanish version of the CY-BOCS reliable and valid instrument, useful for both clinicians and researchers in child and adolescent OCD assessment.


Assuntos
Idioma , Transtorno Obsessivo-Compulsivo/diagnóstico , Inquéritos e Questionários , Adolescente , Criança , Feminino , Humanos , Masculino , Reprodutibilidade dos Testes
6.
Rev. méd. Hosp. Gen. Méx ; 61(2): 85-90, abr.-jun. 1998. tab
Artigo em Espanhol | LILACS | ID: lil-248076

RESUMO

Se presentan los resultados de un estudio clínico abierto binacional, no controlado, llevado a cabo en 85 pacientes hospitalizados con infección complicada del tracto genitourinario o pielonefritis aguda no complicada, tratados con 1 g de cefodizima una vez al día, administrada parenteralmente por inyección intramuscular o intravenosa o perfusión, durante siete a 10 días (mínimo cinco días y máximo 14). El objetivo principal fue evaluar la eficacia y seguridad del tratamiento. La tasa de curación clínica fue alcanzada en el 92.7 por ciento de los pacientes tratados con cefodizima, observando una marcada remisión de los signos y síntomas clínicos al final del tratamiento. La erradicación bacteriológica fue observada en 95.9 por ciento de los enfermos. El microorganismo aislado con mayor frecuencia fue Eschirichia coli (80.2 por ciento). La cefodizima fue bien tolerada, con escasos y leves eventos adversos. Se concluye que 1 g de cefodizima administrada parenteralmente una vez al día en pacientes hospitalizados con infección complicada de vías urinaria con pielonefritis aguda no complicada es un tratamiento eficaz y seguro


Assuntos
Humanos , Pielonefrite/tratamento farmacológico , Infecções Urinárias/complicações , Infecções Urinárias/microbiologia , Infecções Urinárias/tratamento farmacológico , Cefalosporinas/administração & dosagem , Cefalosporinas/uso terapêutico , Resultado do Tratamento , Escherichia coli/isolamento & purificação , Anti-Infecciosos Urinários/administração & dosagem , Anti-Infecciosos Urinários/uso terapêutico , Relação Dose-Resposta a Droga , Urinálise
7.
Rev. méd. Hosp. Gen. Méx ; 61(2): 91-6, abr.-jun. 1998. tab
Artigo em Espanhol | LILACS | ID: lil-248077

RESUMO

Se presentan los resultados de un estudio clínico abierto, no controlados, binacional, conducido en 73 pacientes hospitalizados con infecciones de vías respiratorias bajas adquiridas en la comunidad, tratados con 1 g de cefodizima una vez al días (OAD) administrada parenteralmente por inyección intramuscular, intravenosa o por infusión endovenosa. El objetivo fue evaluar la eficacia y seguridad del medicamento. La curación clínica, se evaluó por la desparición y/o mejoría de los síntomas relacionados a la infección (esputo purulento, tos, disnea y dolor torácico) y la resolución de la fiebre (ó 38ºC). La tasa de éxito se obtuvo en el 92.3 por ciento de los pacientes. La erradicación bacteriológica fue del 98 por ciento. Los microorganismos patógenos aislados con mayor frecuencia fueron: S. pneumoniae (53 por ciento), S aureus (20 por ciento) y K. pneumoniae (10 por ciento). En tres pacientes, los eventos adversos clínicos fueron considerados posiblemente relacionados con la medicación en estudio. Los resultados clínicos muestran que 1 g de cefodizima adminstrada una vez al día es un tratamiento eficaz y seguro en el tratamiento de pacientes adultos hospitalizados con neumonía adquirida en la comunidad


Assuntos
Humanos , Adulto , Pessoa de Meia-Idade , Infecções Respiratórias/etnologia , Infecções Respiratórias/microbiologia , Infecções Respiratórias/tratamento farmacológico , Infecções Bacterianas/tratamento farmacológico , Cefalosporinas/administração & dosagem , Cefalosporinas/uso terapêutico , Relação Dose-Resposta a Droga , Escarro/efeitos dos fármacos , Resultado do Tratamento , Tosse/etiologia , Avaliação de Medicamentos
8.
Trans R Soc Trop Med Hyg ; 92(6): 663-6, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-10326116

RESUMO

Sixty-six patients with human immunodeficiency virus infection and diarrhoea caused by Cryptosporidium parvum were enrolled in a double-'blind' placebo-controlled study to evaluate the safety and efficacy of nitazoxanide in the treatment of cryptosporidiosis related to the acquired immune deficiency syndrome. Patients were randomly assigned to one of 3 treatment groups and received either 500 mg twice daily of nitazoxanide, 1000 mg twice daily of nitazoxanide, or placebo orally for 14 d; the patients on nitazoxanide then crossed over to placebo while the placebo patients crossed over to nitazoxanide therapy at either the high or low dose depending on their randomization. Three post-treatment faecal examinations were conducted on days 15, 22 and 29 following initiation of treatment: patients were considered 'cured' if none revealed any C. parvum oocysts. Both doses of nitazoxanide produced parasitological cure rates superior to the placebo responses (12/19 [63%, P = 0.016] for patients receiving 1 g/d and 10/15 [67%, P = 0.013] for those receiving 2 g/d). Parasitological cure was correlated with the complete resolution of the diarrhoeal syndrome in 19 of the 22 treated patients who were considered parasitologically cured (86%). Both doses of nitazoxanide were well tolerated by the patients.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Antiprotozoários/uso terapêutico , Criptosporidiose/tratamento farmacológico , Diarreia/tratamento farmacológico , Tiazóis/uso terapêutico , Adulto , Animais , Contagem de Linfócito CD4/efeitos dos fármacos , Criptosporidiose/complicações , Cryptosporidium parvum/isolamento & purificação , Diarreia/parasitologia , Método Duplo-Cego , Feminino , Humanos , Masculino , México , Pessoa de Meia-Idade , Nitrocompostos
9.
Ginecol Obstet Mex ; 62: 226-34, 1994 Aug.
Artigo em Espanhol | MEDLINE | ID: mdl-7959144

RESUMO

Efficiency and security clindamycin vaginal cream (2%) were compared to oral metronidazole's for the treatment of 184 women with symptomatic bacterial vaginosis in a multicentric, randomized, double-blind, controlled study. The treatment was of 7 days duration, using placebo capsules for the clindamycin group and placebo cream for the metronidazole group. Patients were observed during a follow up (4-13 and 20-43 days after completion of therapy). Global results of this treatment indicated that clindamycin vaginal cream offers a similar efficiency than oral metronidazole. Improvement or total healing was 87% for clindamycin and 79% for metronidazole, with no significant differences (p > 0.22). No relapses were observed in the clindamycin group, and 7% in the metronidazole group. The clindamycin group had a failure rate of 3% compared to 15% in the oral metronidazole group. Both drugs were well tolerated. Side effects more frequently reported were vulvovaginal irritation and cervicitis/vaginitis. The only side effect that could have been classified as serious was a generalized rash in a patient receiving metronidazole. It was concluded that clindamycin vaginal cream (2%) is an efficient and secure alternative to oral metronidazole for the treatment of bacterial vaginosis being the elective therapy for pregnant women in their first gestational trimester.


Assuntos
Clindamicina/uso terapêutico , Metronidazol/uso terapêutico , Cremes, Espumas e Géis Vaginais , Vaginose Bacteriana/tratamento farmacológico , Administração Oral , Adolescente , Adulto , Clindamicina/administração & dosagem , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Metronidazol/administração & dosagem , Pessoa de Meia-Idade
10.
Arch AIDS Res ; 6(3): 183-95, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-12317784

RESUMO

PIP: This study was designed to compare the safety/efficacy of the treatment of 2% clindamycin vaginal cream and oral metronidazole in 184 women with bacterial vaginosis. This was a randomized, prospective, multicenter, double-blind, controlled study. Patients were randomized to either Clindamycin phosphate vaginal cream 2%, 5 gm intravaginally at bedtime, and placebo oral metronidazole capsules taken twice daily, or oral metronidazole capsules, 500 mg, taken twice daily, and placebo clindamycin vaginal cream, 5 gm to be administered intravaginally at bedtime. All treatments were for 7 days. Patients were seen for followup at 4-13 days and 20-43 days after completion of protocol therapy. 2 investigators in Mexico City enrolled a total of 184 patients (91 clindamycin and 93 metronidazole). 1 patient never received drugs after enrollment, leaving 183 valuable for safety. A total of 114 were valuable for efficacy. Protocol regimens were comparable in efficacy (p=0.22) and the percentage of cure/improvement was 87% in the clindamycin group compared to 79% in the metronidazole group. No relapse was observed in the clindamycin group, as opposed to 7% in the metronidazole group. The clindamycin group had a failure of 13% while this was 15% in the metronidazole group. Both treatments were well-tolerated. Most of the events were either vulvovaginal irritation upon application of the study drug, or the development of vaginitis/cervicitis. The 1 event classified as serious in this study (metronidazole group) was generalized rash which, in the opinion of the investigator, was related to the study drug. There were 4 nongenital tract side effects (1 gastrointestinal, 2 dermatologic, and 1 allergy) all in the metronidazole group. The authors can conclude that clindamycin 2% vaginal cream is at least as effective as orally administered metronidazole for the treatment of bacterial vaginosis in nonpregnant women.^ieng


Assuntos
Antibacterianos , Técnicas de Laboratório Clínico , Método Duplo-Cego , Características da População , Terapêutica , Vaginite , América , Demografia , Países em Desenvolvimento , Diagnóstico , Doença , América Latina , México , América do Norte , Preparações Farmacêuticas , População , Pesquisa , Vagina
11.
Parasite Immunol ; 9(6): 757-60, 1987 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-2893327

RESUMO

Worldwide prevalence of amoebiasis is estimated at 4 x 10(8) cases/year, yet only one of about 300 individuals harbouring Entamoeba histolytica suffers tissue invasion and these cases are mostly concentrated in certain areas of Asia, Africa and Latin America. Patients with amoebic abscess of the liver (AAL) represent only a small fraction of that. These contrasting figures have been tentatively explained on the one hand through variations in sex, immunocompetence, nutritional and other socioeconomic features of the host, and on the other hand through differences in parasite virulence. In order to explore a possible association between the major histocompatibility complex (MHC) and AAL susceptibility, we studied the HLA profile in 31 Mexican mestizos with AAL and compared it to race and socioeconomically matched controls. Mexican mestizo patients with AAL revealed a significant increase in HLA-Bw16 and HLA-DR3 which could suggest an HLA-related susceptibility to liver invasion by E. histolytica.


Assuntos
Abscesso/imunologia , Amebíase/imunologia , Entamebíase/imunologia , Antígenos HLA/análise , Hepatopatias/imunologia , Animais , Entamoeba histolytica/imunologia , Feminino , Humanos , Masculino , México
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA